Between the two types of TTR silencers, the Food and Drug Administration (FDA) reports that patisiran is effective at alleviating the symptoms of CM in patients with ATTR who have a mixed phenotype, as the clinical trial to determine the effectiveness of this treatment, APOLLO, showed a decrease in the morbidity and mortality regarding the cardiovascular phenotype [20]. The gene discussed is TTR; the disease is cutaneous mastocytosis.